NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal (STA)

Sofosbuvir for treating chronic hepatitis C [ID654]

Matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
Manufacturers/sponsors	General
Gilead Sciences (sofosbuvir)	Allied Health Professionals Federation
	Board of Community Health Councils in
Patient/carer groups	Wales
Action on Hepatitis C	British National Formulary
Addiction Today (Addiction Recovery	Care Quality Commission
Foundation)	Commissioning Support Appraisals
Afiya Trust	Service
African Health Policy Network	Department of Health, Social Services
Alliance	and Public Safety for Northern Ireland
• AVERT	Healthcare Improvement Scotland
Black Health Agency	 Medicines and Healthcare Products
British Liver Trust	Regulatory Agency
Compass UK	 National Association of Primary Care
Drugs Action	National Pharmacy Association
Drugscope	NHS Alliance
Equalities National Council	NHS Commercial Medicines Unit
GMFA - The Gay Men's Health	NHS Confederation
Charity	Scottish Medicines Consortium
Haemophilia Alliance	
Haemophilia Society	Comparator manufacturer(s)
Hepatitis A –Z	BioPartners GmBH (ribavirin)
Hepatitis C Trust	Janssen (telaprevir)
Muslim Council of Britain	Meda Pharmaceuticals (ribavirin)
Muslim Health Network	Merck Sharp & Dohme (boceprevir,
NAM Publications	peginterferon alpha- 2b, ribavirin)
National AIDS Trust	Mylan UK (ribavirin)
Positively UK	Roche Products (peginterferon alfa-2a,
South Asian Health Foundation	ribavirin)
Specialised Healthcare Alliance	Teva UK (ribavirin)
Terrence Higgins Trust	Polovent records groups
Transplant Support Network	Relevant research groups
UK Harm Reduction Alliance	Centre for Sexual Health & HIV Research
Youth Net	
	Cochrane Hepato-Biliary GroupFoundation for Liver Research
Professional groups	Foundation for Liver ResearchHealth Research Authority
Association for Clinical Biochemistry	MDO OF COLETION INC.
	MRC Clinical Trials Unit

National Institute for Health and Care Excellence

Matrix for the technology appraisal of sofosbuvir for treating chronic hepatitis C

Issue date: November 2013

Page 1 of 4

Consultees Commentators (no right to submit or appeal) Microbiology Group National Institute of Health Research Association of Nurses in Substance Research Institute for the Care of Older Abuse People Association of Surgeons of Great Britain **Evidence Review Group** British Association for Sexual Health Southampton Health Technology Assessment Centre (SHTAC) and HIV British Association for the Study of the National Institute for Health Research Health Technology Assessment Programme British Association for the Study of the Liver Nurses Forum <u>Associated Guideline Groups</u> **British Geriatrics Society** National Clinical Guidelines Centre **British HIV Association British Infection Association** Associated Public Health Groups **British Liver Nurses Forum** Public Health England British Society of Gastroenterology Public Health Wales NHS Trust **British Viral Hepatitis Group** Haemophilia Nurses Association **HCV** Action **Health Protection Agency** Hepatitis Nurse Specialist Forum Infection Control Nurses Association Medical Foundation for AIDS & Sexual Health NHS Blood and Transplant Royal College of Anaesthetists Royal College of General Practitioners Royal College of Nursing Royal College of Pathologists Royal College of Physicians Royal College of Surgeons Royal Pharmaceutical Society Royal Society of Medicine Society for General Microbiology **United Kingdom Clinical Pharmacy** Association United Kingdom Clinical Virology Network United Kingdom Haemophilia Centre **Doctors' Organisation** Others Department of Health NHS England

Consultees	Commentators (no right to submit or appeal)
NHS Cumbria CCG	
 NHS Redditch and Bromsgrove CCG 	
Welsh Government	

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies;

Healthcare Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the *British National Formulary*.

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

Evidence Review Group (ERG)

An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.

.

¹ Non manufacturer consultees are invited to submit statements relevant to the group they are representing.